Levosimendan Eql Pharma (Levosimendan)

Levosimendan enhances the sensitivity of cardiac troponin C to calcium, which increases the strength of heart muscle contraction without raising intracellular calcium levels. It also opens ATP‑sensitive potassium channels in blood vessels, causing vasodilation and lowering afterload, thereby improving overall cardiac output.

The dosing regimen for levosimendan is determined by the prescribing clinician based on the patient's clinical condition, weight, and response. The medication is administered intravenously under close medical supervision, and the exact infusion rate and duration are individualized for each patient.

The safety of levosimendan in pregnancy and lactation has not been established. It should be used only if the potential benefits justify the potential risks to the fetus or infant, and it is generally avoided unless no suitable alternatives are available.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Unlike traditional inotropes that increase intracellular calcium and may raise the risk of arrhythmias, levosimendan sensitises troponin C to existing calcium, providing contractile support with a lower pro‑arrhythmic profile. It also adds vasodilatory effects through potassium‑channel activation, which many other inotropes lack.

Levosimendan injectable solution must be stored at 2‑8 °C, protected from light, and should not be frozen or shaken. Keep the product in its original packaging until use and ensure the cold‑chain is maintained during transport and storage.

Levosimendan is given as an intravenous infusion, typically initiated with a loading dose followed by a continuous maintenance infusion. Administration is performed in a clinical setting where blood pressure, heart rate and cardiac output can be continuously monitored.

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia and rare anaphylactic reactions. Patients should be closely monitored for changes in blood pressure, heart rhythm and signs of allergic response throughout the infusion.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, those with severe hypotension unresponsive to treatment, and individuals with significant obstructive cardiac lesions where increased contractility could be harmful. Caution is also advised in severe hepatic impairment.